The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

In order to evaluate the effect of CYP3A5*3 allele on the pharmacokinetics of sildenafil, udenafil, and vardenafil, the clinical trial using a single oral dose was conducted in Korean healthy male subjects whose genotype of CYP3A5 had been determined.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Inje University
• Treatments: Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Udenafil; Vardenafil Dihydrochloride

Criteria

Inclusion Criteria:

• Healthy male subject whose CYP3A5 genotype was determined

Exclusion Criteria:

• Subject whose CYP3A5 genotype was not determined